Platform Expansion

About Vomaris Innovations

Vomaris Innovations is a commercial-stage medical device company with a unique bioelectric technology platform for antimicrobial wound care. Its flagship product, Procellera (also available OTC as PowerHeal), uses a patented matrix of microcell batteries to generate an electric field that targets bacterial biofilm and supports the body's healing process. The company addresses a significant unmet need in chronic and surgical wound management, with products marketed through prescription, over-the-counter channels, and via a partnership with Arthrex for orthopedic applications.

About Mymee

Mymee is a New York-based digital therapeutics company founded in 2016, targeting the large and underserved market of patients with autoimmune diseases and long COVID who experience uncontrolled symptoms. Its core offering is a personalized care platform combining a mobile app, a proprietary data analytics engine, and dedicated health coaches to help patients identify and avoid individual triggers, leading to clinically validated reductions in pain, fatigue, and other symptoms. The company has garnered support from industry leaders and published peer-reviewed research, positioning itself as a novel, data-driven adjunct to conventional autoimmune care.

About Vista.ai

Vista AI is a private, commercial-stage company addressing critical bottlenecks in MRI access through automation. Its core product is FDA-cleared software that automates cardiac MRI scanning protocols, demonstrably increasing throughput, consistency, and accessibility while reducing technologist burnout. Backed by clinical validation from leading institutions like Brigham and Women's Hospital, the company is positioned to expand its automation platform to other anatomical areas, leveraging AI to tackle staffing shortages and growing imaging demand.

About Rune Labs

Rune Labs is a private, San Francisco-based digital health company founded in 2018, operating at the intersection of neuroscience, AI, and data analytics. Its core offering is the StrivePD ecosystem, an FDA-cleared platform that uses the Apple Watch to collect Parkinson's symptom data, enabling personalized patient care and providing real-world datasets for clinical research. The company generates revenue by offering its StriveStudy platform and data services to life sciences companies for clinical trials, real-world evidence, and commercial support, while also serving clinicians and patients directly. Rune Labs has established key partnerships with healthcare providers like Kaiser Permanente and biotech firms like BlueRock Therapeutics.

About Uh-Oh Labs

Uh-Oh Labs is a private, commercial-stage diagnostics company that has successfully launched its first product: the FDA-authorized UOL COVID-19 Test system. The company's proprietary Loop-de-Loop™ RT-LAMP platform forms the basis for a portable, rapid, and cost-effective molecular diagnostics system, which has garnered significant non-dilutive funding from the NIH's RADx initiative. With a core focus on infectious disease diagnostics, Uh-Oh Labs is leveraging its initial commercial foothold and strong financial backing to develop additional tests for its platform, targeting expansion beyond COVID-19.

About Linear Health Sciences

Linear Health Sciences, founded in 2015 and based in Oklahoma City, USA, is a private medical device company addressing the significant clinical and economic problem of unintentional medical tubing dislodgement. The company has developed the Orchid SRV, a safety-release valve that acts as a mechanical fail-safe, separating under tension to protect the catheter site and prevent complications. Backed by survey data highlighting the prevalence of dislodgements, the company positions its technology as a platform applicable to various tubing types (PIV, PICC, Midline, Central Lines), with an initial focus on the high-risk pediatric patient population. The company appears to be in an early commercial or pre-revenue stage, seeking hospital adoption for its first product.

About Sequel Med Tech

Sequel Med Tech is a private, commercial-stage medical device company pioneering a novel automated insulin delivery (AID) system called twiist. The system differentiates itself through direct volume measurement of insulin, pharmacy channel distribution for affordability, and utilization of the Tidepool algorithm. Co-founded by renowned inventor Dean Kamen and other healthcare veterans, Sequel aims to address the significant unmet need in the diabetes market, where a majority of insulin-requiring patients are not yet using AID technology.

About ECI Therapeutics

ECI Therapeutics is a private, preclinical-stage biotech leveraging a unique platform that fuses human platelet-rich plasma-derived growth factors with proprietary biomaterials (hyaluronic acid/chitosan) to create sustained-release therapeutics for tissue repair. Its initial focus is on significant ophthalmic markets, targeting neurotrophic keratitis (a rare disease) and the large, underserved dry eye disease population, with a broader pipeline extending into wound and burn care. Founded in 2018 and based in Cambridge, MA, the company is positioned to address conditions with high unmet need through a potentially safer, more efficacious, and patient-friendly biologic approach.

About LoQus23 Therapeutics

LoQus23 Therapeutics is a private, preclinical-stage biotech targeting a novel mechanism in repeat expansion disorders like Huntington's disease. The company, founded by experienced industry veterans, is developing small molecules designed to inhibit somatic expansion of DNA repeats, aiming to halt disease progression at its source. Backed by the Dementia Discovery Fund and led by a team with deep neuroscience and drug discovery expertise, LoQus23 is positioned to address a high-unmet medical need with a potentially disease-modifying approach.

About Amygdala Neurosciences

Amygdala Neurosciences is pioneering a novel pharmacological approach to treating addiction by targeting the aldehyde dehydrogenase type 2 (ALDH2) enzyme. Its lead asset, ANS-858, is an oral, reversible ALDH2 inhibitor in preclinical development with potential applications across multiple substance use disorders, starting with alcohol use disorder. The company is led by a seasoned management team with deep experience in founding, developing, and commercializing successful biotech ventures. Amygdala's strategy is based on the premise that ALDH2 inhibition can reduce cravings and relapse, addressing a significant unmet medical need in a large and underserved market.

About Amygdala Neurosciences

Amygdala Neurosciences is pioneering a novel pharmacological approach to treating addiction by targeting the aldehyde dehydrogenase type 2 (ALDH2) enzyme. Its lead asset, ANS-858, is an oral, reversible ALDH2 inhibitor in preclinical development with potential applications across multiple substance use disorders, starting with alcohol use disorder. The company is led by a seasoned management team with deep experience in founding, developing, and commercializing successful biotech ventures. Amygdala's strategy is based on the premise that ALDH2 inhibition can reduce cravings and relapse, addressing a significant unmet medical need in a large and underserved market.

About Amygdala Neurosciences

Amygdala Neurosciences is pioneering a novel pharmacological approach to treating addiction by targeting the aldehyde dehydrogenase type 2 (ALDH2) enzyme. Its lead asset, ANS-858, is an oral, reversible ALDH2 inhibitor in preclinical development with potential applications across multiple substance use disorders, starting with alcohol use disorder. The company is led by a seasoned management team with deep experience in founding, developing, and commercializing successful biotech ventures. Amygdala's strategy is based on the premise that ALDH2 inhibition can reduce cravings and relapse, addressing a significant unmet medical need in a large and underserved market.

About Epitopoietic Research

ERC is a Belgian clinical-stage biotech pioneering a unique, patented cell-based immunotherapy for solid tumors, with a primary focus on recurrent glioblastoma (GBM). Its lead vaccine, Gliovac/ERC1671, combines autologous and allogeneic tumor cells to stimulate a potent anti-cancer immune response and has shown promising survival extensions in compassionate use. While advancing its GBM program through clinical trials, the company is also leveraging its platform to develop vaccines for viral infections, though it faces challenges typical of early-stage biotechs, including clinical validation and funding.

About Samphire Neurosciences

Samphire Neurosciences is a private, commercial-stage biotech/medtech hybrid targeting the neuroscience of women's health. Its core platform consists of wearable neurostimulation devices (Nettle™/Lutea™) paired with a cycle-tracking software service (CycleSync™), offering a holistic, non-pharmacological solution for conditions like PMS, PMDD, and dysmenorrhea. The company is already generating revenue through direct-to-consumer sales of its hardware and subscription software, supported by claims of clinical validation from its own studies. It operates in the high-growth femtech and digital therapeutics space, competing against both traditional pharmaceuticals and wellness products.

About Samphire Neurosciences

Samphire Neurosciences is a private, commercial-stage biotech/medtech hybrid targeting the neuroscience of women's health. Its core platform consists of wearable neurostimulation devices (Nettle™/Lutea™) paired with a cycle-tracking software service (CycleSync™), offering a holistic, non-pharmacological solution for conditions like PMS, PMDD, and dysmenorrhea. The company is already generating revenue through direct-to-consumer sales of its hardware and subscription software, supported by claims of clinical validation from its own studies. It operates in the high-growth femtech and digital therapeutics space, competing against both traditional pharmaceuticals and wellness products.

About Samphire Neurosciences

Samphire Neurosciences is a private, commercial-stage biotech/medtech hybrid targeting the neuroscience of women's health. Its core platform consists of wearable neurostimulation devices (Nettle™/Lutea™) paired with a cycle-tracking software service (CycleSync™), offering a holistic, non-pharmacological solution for conditions like PMS, PMDD, and dysmenorrhea. The company is already generating revenue through direct-to-consumer sales of its hardware and subscription software, supported by claims of clinical validation from its own studies. It operates in the high-growth femtech and digital therapeutics space, competing against both traditional pharmaceuticals and wellness products.

About MultiOmic Health

MultiOmic Health is an AI-driven precision medicine company targeting the massive and costly cardio-renal-metabolic disease space. The company has built a proprietary platform that uses multi-omics data and longitudinal clinical phenotyping to discover patient subgroups and develop targeted therapeutics and companion diagnostics. Led by a seasoned team with deep biopharma and data science experience, the company is in a pre-clinical, pre-revenue stage, building a global patient registry and advancing its initial programs in chronic kidney disease.

About bioAffinity Technologies

bioAffinity Technologies is a public biotech company focused on non-invasive, early-stage cancer diagnostics and targeted treatments. Its core achievement is the commercial launch of CyPath® Lung, a Laboratory Developed Test (LDT) with compelling clinical data (92% sensitivity, 87% specificity for small nodules) that addresses the critical diagnostic gap following indeterminate low-dose CT scans. The company's strategy is to commercialize this first product through its CLIA-certified lab subsidiary while advancing its porphyrin-based platform for broader diagnostic and therapeutic applications in oncology.

Therapeutic Areas